Literature DB >> 28624005

Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: Classification tree analysis applying capsule and septum.

Ji Hye Min1, Young Kon Kim2, Seo-Youn Choi3, Woo Kyoung Jeong1, Won Jae Lee1, Sang Yun Ha4, Soohyun Ahn5, Hyeon Seon Ahn5.   

Abstract

OBJECTIVES: To assess the usefulness of classification tree analysis (CTA) for discrimination of hepatocellular carcinoma (HCC) with target sign on hepatobiliary phase (HBP) and/or diffusion-weighted image (DWI) from intrahepatic cholangiocarcinoma (ICC).
METHODS: This retrospective study was approved by the institutional review board. From among the 811 patients with histopathologically proven 79 ICCs and 732 HCCs, 69 patients with 69 (87.3%) ICCs and 115 patients with 115 HCCs (15.7%) including 25 scirrhous HCCs and 10 HCCs with central scar that showed the target sign either on HBP or on DWI were included. Two radiologists evaluated the presence of capsule, septum, and arterial enhancement pattern on MR imaging. Capsule, septum, arterial enhancement pattern, and target sign on HBP or DWI were used to classify the tumors using CTA.
RESULTS: On CTA, capsule was the initial predictor for assessing the probability of tumors being HCC. The CTA model demonstrated a sensitivity of 86.1%, specificity of 76.8%, and accuracy of 82.6% for discriminating between ICCs and HCCs. In 115 HCCs, only 16 (13.9%) tumors were misclassified as high probability of ICC, and 64.0% (16/25) scirrhous HCCs and 90.0% (9/10) HCCs with central scar were correctly classified as high probability of HCC.
CONCLUSIONS: Target sign either on HBP or on DWI was shown in 87.3% (69/79) of ICCs and 15.7% (115/732) of HCCs. The CTA applying capsule and septum may be useful for guiding correct diagnosis of atypical HCCs with the target sign from ICCs.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Cholangiocarcinoma; Diffusion-weighted image; Gadoxetic acid; Hepatobiliary phase; Hepatocellular carcinoma; Target sign

Mesh:

Substances:

Year:  2017        PMID: 28624005     DOI: 10.1016/j.ejrad.2017.04.008

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  13 in total

1.  Different MR features for differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma according to tumor size.

Authors:  Ting Ni; Xiao-Sha Shang; Wen-Tao Wang; Xin-Xing Hu; Meng-Su Zeng; Sheng-Xiang Rao
Journal:  Br J Radiol       Date:  2018-06-05       Impact factor: 3.039

2.  Fibronodular hepatocellular carcinoma-a new variant of liver cancer: clinical, pathological and radiological correlation.

Authors:  Jonathan Tefera; Margarita Revzin; Julius Chapiro; Lynn Jeanette Savic; David Mulligan; Ramesh Batra; Tamar Taddei; Dhanpat Jain; Xuchen Zhang
Journal:  J Clin Pathol       Date:  2020-05-19       Impact factor: 3.411

3.  Values of MRI Imaging Presentations in the Hepatobiliary Phase, DWI and T2WI Sequences in Predicting Pathological Grades of Intrahepatic Mass-Forming Cholangiocarcinoma.

Authors:  Li-Hong Xing; Li-Yong Zhuo; Jia-Ning Wang; Yan Zhang; Feng-Ying Zhu; Chu Wang; Xiao-Ping Yin; Bu-Lang Gao
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

4.  Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging.

Authors:  Seo-Youn Choi; Young Kon Kim; Ji Hye Min; Tae Wook Kang; Woo Kyoung Jeong; Soohyun Ahn; Hojeong Won
Journal:  Eur Radiol       Date:  2018-01-15       Impact factor: 5.315

5.  Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI.

Authors:  Ryan L Brunsing; Kathryn J Fowler; Takeshi Yokoo; Guilherme Moura Cunha; Claude B Sirlin; Robert M Marks
Journal:  Hepatoma Res       Date:  2020-09-01

6.  Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma.

Authors:  Yueming Li; Jianwei Chen; Shuping Weng; Chuan Yan; Rongping Ye; Yuemin Zhu; Liting Wen; Dairong Cao; Jinsheng Hong
Journal:  Ann Transl Med       Date:  2021-01

Review 7.  Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting.

Authors:  Federica Vernuccio; Domenico Salvatore Gagliano; Roberto Cannella; Ahmed Ba-Ssalamah; An Tang; Giuseppe Brancatelli
Journal:  Insights Imaging       Date:  2021-01-12

8.  Multi-parameter gene expression profiling of peripheral blood for early detection of hepatocellular carcinoma.

Authors:  Hui Xie; Yao-Qin Xue; Peng Liu; Peng-Jun Zhang; Sheng-Tao Tian; Zhao Yang; Zhi Guo; Hua-Ming Wang
Journal:  World J Gastroenterol       Date:  2018-01-21       Impact factor: 5.742

Review 9.  Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers.

Authors:  Yeun-Yoon Kim; Mi-Suk Park; Khalid Suliman Aljoqiman; Jin-Young Choi; Myeong-Jin Kim
Journal:  Clin Mol Hepatol       Date:  2019-01-21

10.  Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.

Authors:  Lang Chen; Furong Zeng; Lei Yao; Tongdi Fang; Mengting Liao; Jing Long; Liang Xiao; Guangtong Deng
Journal:  Cancer Med       Date:  2020-01-05       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.